The Private Equity team guided BioLabs on the launch of BioLabs|TUM, a new biotechnology innovation hub in central Munich, with TUM Venture Labs and Eli Lilly and Company. The initiative aims to empower early-stage biotech startups by providing access to state-of-the-art lab infrastructure, expert mentoring, and global industry networks. BioLabs|TUM will offer fully equipped laboratories and office space for 15–20 startups. The hub is designed to accelerate the development of breakthrough therapies by connecting scientific talent with venture capital and pharmaceutical expertise.
BioLabs is a network of shared laboratory facilities located in key geographies within well-established as well as more nascent biotech innovation clusters in the US, Japan, France and Germany. BioLabs offers a unique environment of coworking spaces that pair fully equipped and supported laboratories with furnished office space, and active community-building. BioLabs provides entrepreneurs with unparalleled access to capital through its affiliated venture fund Mission BioCapital and numerous industry partnerships. These fertile, supportive ecosystems allow young companies to shift their focus from lab buildout and operations to experimentation and innovation so that they can quickly reach their scientific potential and achieve business success. The BioLabs network of coworking lab facilities now comprises 17 sites, with additional sites under development. Munich will be the third lab location for BioLabs in Germany after Heidelberg and Berlin.
The Goodwin team was led by Markus Käpplinger and further consisted of Bastian Schmack and Nadine Gommel (all Frankfurt) and James Barrett (Boston).
For more information on the deal, please read the press release.